245 related articles for article (PubMed ID: 10854529)
1. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Szostak MJ; Kyprianou N
Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
[TBL] [Abstract][Full Text] [Related]
2. Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review).
Hill B; Kyprianou N
Oncol Rep; 2002; 9(6):1151-6. PubMed ID: 12375010
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target.
Bruckheimer EM; Kyprianou N
Cell Tissue Res; 2000 Jul; 301(1):153-62. PubMed ID: 10928288
[TBL] [Abstract][Full Text] [Related]
4. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
5. Management strategies for locally advanced prostate cancer.
Jani AB
Drugs Aging; 2006; 23(2):119-29. PubMed ID: 16536635
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer.
Kyprianou N
World J Urol; 1994; 12(6):299-303. PubMed ID: 7881465
[TBL] [Abstract][Full Text] [Related]
7. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
8. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for localized carcinoma of the prostate: the role of external beam radiation therapy.
Khil MS; Kim JH
Henry Ford Hosp Med J; 1992; 40(1-2):103-7. PubMed ID: 1428958
[TBL] [Abstract][Full Text] [Related]
10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
11. Irradiation in relapsing carcinoma of the prostate.
Perez CA; Cosmatos D; Garcia DM; Eisbruch A; Poulter CA
Cancer; 1993 Feb; 71(3 Suppl):1110-22. PubMed ID: 7679040
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
13. Prognostic markers in clinically localized prostate cancer.
Pettaway CA
Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
[TBL] [Abstract][Full Text] [Related]
14. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis.
Sklar GN; Eddy HA; Jacobs SC; Kyprianou N
J Urol; 1993 Nov; 150(5 Pt 1):1526-32. PubMed ID: 8411447
[TBL] [Abstract][Full Text] [Related]
15. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
[TBL] [Abstract][Full Text] [Related]
16. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer?
Merrick GS; Butler WM; Lief JH; Dorsey AT
Tech Urol; 2001 Mar; 7(1):12-9. PubMed ID: 11272667
[TBL] [Abstract][Full Text] [Related]
17. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
Mackey TJ; Borkowski A; Amin P; Jacobs SC; Kyprianou N
Urology; 1998 Dec; 52(6):1085-90. PubMed ID: 9836559
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
19. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
